A double-blind comparison of sulpiride with chlordiazepoxide in neurosis. 1976

M Toru, and H Moriya, and K Yamamoto, and Y Shimazono

The therapeutic effectiveness of sulpiride on various types of neurosis was compared with that of chlordiazepoxide on a double-blind basis. Global improvement, effectiveness on various types of neurosis, and side effects were studied for a period of two weeks. The subjects consisted of 41 males and 32 females. Neurosis including borderline case and vegetative dystonia was divided into eight different subtypes comprising borderline, neurasthenic state, hypochondria, obsessive neurosis or phobia, depressive neurosis, anxiety neurosis, vegetative dystonia, and others. A newly devised matched-pair method of comparison was employed to achieve even distribution of the eight subtypes of neurosis between the two drug groups. As a result 40 patients fell in the sulpiride group and 33 patients in the chlordiazepoxide group. The backgrounds of the paired patients matched closely. The daily dose was uniformly 150 mg for sulpiride and 30 mg for chlordiazepoxide in the first week but was raised (or lowered in some cases) to 225 mg and 45 mg, respectively, in the second week according to severity. The rate of global improvement was 79% for the sulpiride group and 90% for chlordiazepoxide group, and the difference did not reach statistical significance. Improvement by manifestation (13 symptom items) and type of neurosis also matched. Side effects occurred at a rate of 28% (sulpiride group) and 30% (chlordiazepoxide group), and also matched closely in incidence and variety. The authors concluded that sulpiride in appropriate doses is useful in the treatment of neurosis without causing extrapyramidal side effects.

UI MeSH Term Description Entries
D008297 Male Males
D009497 Neurotic Disorders Disorders in which the symptoms are distressing to the individual and recognized by him or her as being unacceptable. Social relationships may be greatly affected but usually remain within acceptable limits. The disturbance is relatively enduring or recurrent without treatment. Neuroses,Psychoneuroses,Disorder, Neurotic,Disorders, Neurotic,Neurotic Disorder
D002707 Chlordiazepoxide An anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal. Methaminodiazepoxide,7-Chloro-2-methylamino-5-phenyl-3H-1,4-benzodiazepine-4-oxide,7-Chloro-N-methyl-5-phenyl-3H-1,4-benzodiazepin-2-amine 4-oxide,Chlordiazepoxide Hydrobromide,Chlordiazepoxide Hydrochloride,Chlordiazepoxide Monohydrochloride,Chlordiazepoxide Perchlorate,Chlozepid,Elenium,Librium,7 Chloro 2 methylamino 5 phenyl 3H 1,4 benzodiazepine 4 oxide,7 Chloro N methyl 5 phenyl 3H 1,4 benzodiazepin 2 amine 4 oxide,Hydrobromide, Chlordiazepoxide,Hydrochloride, Chlordiazepoxide,Monohydrochloride, Chlordiazepoxide,Perchlorate, Chlordiazepoxide
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013469 Sulpiride A dopamine D2-receptor antagonist. It has been used therapeutically as an antidepressant, antipsychotic, and as a digestive aid. (From Merck Index, 11th ed) Aiglonyl,Arminol,Deponerton,Desisulpid,Digton,Dogmatil,Dolmatil,Eglonyl,Ekilid,Guastil,Lebopride,Meresa,Pontiride,Psicocen,Sulp,Sulperide,Sulpitil,Sulpivert,Sulpor,Synédil,Tepavil,Vertigo-Meresa,neogama,vertigo-neogama,Vertigo Meresa,vertigo neogama

Related Publications

M Toru, and H Moriya, and K Yamamoto, and Y Shimazono
January 1972, The Journal of clinical pharmacology and new drugs,
M Toru, and H Moriya, and K Yamamoto, and Y Shimazono
January 1984, Acta psychiatrica Scandinavica. Supplementum,
M Toru, and H Moriya, and K Yamamoto, and Y Shimazono
September 1992, Fortschritte der Medizin,
M Toru, and H Moriya, and K Yamamoto, and Y Shimazono
January 1967, Psychosomatics,
M Toru, and H Moriya, and K Yamamoto, and Y Shimazono
July 1979, Acta psychiatrica Scandinavica,
M Toru, and H Moriya, and K Yamamoto, and Y Shimazono
October 2013, Asian journal of psychiatry,
M Toru, and H Moriya, and K Yamamoto, and Y Shimazono
August 1962, Journal of neuropsychiatry,
M Toru, and H Moriya, and K Yamamoto, and Y Shimazono
January 1973, Current medical research and opinion,
M Toru, and H Moriya, and K Yamamoto, and Y Shimazono
April 1967, Diseases of the nervous system,
M Toru, and H Moriya, and K Yamamoto, and Y Shimazono
May 2009, Journal of studies on alcohol and drugs,
Copied contents to your clipboard!